<To Vertex followers, does anyone out there having an explanation for the increase in short interest (days to cover almost doubled from February to April). Is there some negative info already out there??? If I am not wrong Vertex will present additional Phase II data at the World AIDS Conference in Geneva. Having that in mind isn't it strange to see all these shorts?? Thanks for your comments, Richie3>
Here's the answer: the short interest is almost exactly the same. The avg daily volume is about 1/2. Thus, twice the cover ratio.
That's the math. As for Geneva, the data will not be headline stuff; merely add'l data on ongoing trials (later endpoints). It's likely to get a piece of the pie (see earlier posts by SkinK) as it will be "new" and for salvage, new is better than old, even taking into account resistance etc. But as Fribon points out approval is not imminent (filing hasn't even taken place), and it will make less of a splash even when it comes. Esp. with drugs like ABT 338 already in phase II and moving much faster. Cheers and I guess some day I really should fork over the dough to post on SI.